Warning: The NCBI web site requires JavaScript to function. more...
How safe are the biologicals in treating asthma and rhinitis?
Cox LS.
Allergy Asthma Clin Immunol. 2009 Oct 22;5(1):4.
Related citations
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Allergen injection immunotherapy for seasonal allergic rhinitis.
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001936. Review.
[New administration routes for immunotherapy].
Martorell Aragonés A.
Allergol Immunopathol (Madr). 2000 May-Jun;28(3):93-102. Review. Spanish.
[Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K.
Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.
[Past and future of allergen immunotherapy].
Just J, Goudard E, Grimfeld A.
Arch Pediatr. 2004 Jun;11 Suppl 2:74s-79s. Review. French.
Recent progress in allergen immunotherapy.
Nouri-Aria KT.
Iran J Immunol. 2008 Mar;5(1):1-24. Review.
[Preventive immunotherapy].
Boquete M, Carballada F, Expósito F, González A.
Allergol Immunopathol (Madr). 2000 May-Jun;28(3):89-93. Review. Spanish.
Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
[No authors listed]
BioDrugs. 2002;16(5):380-6.
Advances in upper airway diseases and allergen immunotherapy.
Nelson HS.
J Allergy Clin Immunol. 2007 Apr;119(4):872-80. Epub 2007 Feb 9. Review.
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.
Appropriate and inappropriate use of immunotherapy.
DuBuske LM.
Ann Allergy Asthma Immunol. 2001 Jul;87(1 Suppl 1):56-67. Review.
Allergen immunotherapy: immunomodulatory treatment for allergic diseases.
Cox L.
Expert Rev Clin Immunol. 2006 Jul;2(4):533-46.
Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
Nurmohamed MT.
Drugs. 2009 Oct 22;69(15):2035-43. doi: 10.2165/11318290-000000000-00000.
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL, Figgitt DP.
Drugs. 2003;63(8):803-43. Review.
[Efficacy of immunotherapy in the treatment of asthma].
Martín Muñoz MF.
Allergol Immunopathol (Madr). 2004 May-Jun;32(3):133-41. Review. Spanish.
Botulinum toxin type B for cervical dystonia.
Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C.
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004315. Review.
Regular treatment with salmeterol for chronic asthma: serious adverse events.
Cates CJ, Cates MJ.
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006363. Review.
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, Cooper PJ.
Clin Exp Allergy. 2007 Feb;37(2):197-207.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on